MAY 2 1 2003 ROS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#20, alia 5/9/03

re Application of:

Michael Edge et al.

Serial No.:

09/398,610

Group No.:

1632

Filed:

09/17/1999

Examiner:

Anne Marie Sabrina Wehbe

For:

Transgenically Produced Fusion Proteins

Attorney Docket Number:

GTC-42

RECEIVED

MAY 2 3 2003

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TECH CENTER 1600/2900

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT AFTER THE FIRST OFFICE ACTION ON THE MERITS BUT BEFORE MAILING OF EITHER A FINAL ACTION OR A NOTICE OF ALLOWANCE (37 CFR 1.97(c))

1. Authority

Pursuant to 37 CFR § § 1.56 and 1.97-1.99, the Applicant cites to the Examiner documents containing information which, in good-faith judgment of the Applicant, may be relevant to the subject mater claimed in the above-identified application. The Applicant also encloses copies of the English-language cited documents.

In submitting this Supplemental Information Disclosure Statement, the Applicant makes no representation that a search has been performed, or the extent of any search performed, or that more relevant information does not exist.

In submitting this Supplemental Information Disclosure Statement, the Applicant makes no representation that any document cited in this Supplemental Information Disclosure Statement is, or is considered to be prior art as defined by 35 USC § § 102 and 103.

2. Time of transmittal of accompanying Supplemental Information Disclosure Statement

The Supplemental Information Disclosure Statement transmitted herewith is being filed *after* three months of the filing date of this application *and after* the mailing date of the first Office action on the merits, but *before* the mailing date of either:

05/22/2003 WASFAW1 00000051 502092 09398610

(1) a final action under § 1.113, or

01 FC:1806

180.00 CH

(2) a notice of allowance under § 1.311, whichever occurs first.

CERTIFICATE OF MAILING (37 CFR 1.8a)	
I hereby certify that on May 16, 2003 this correspondence is being deposited with the with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, 22313-1450. Kristin Gould	e United States Postal Service P.O. Box 1450, Alexandria, VA

3. Amount of Fee

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Supplemental Information Disclosure Statement under § 1.97(c).

Fee due \$ 180.00

4. Authority to charge Deposit Account

Please charge this \$180.00 and any other necessary fees which may be required during the entire pendency of this application to Deposit Account No. 502092. A duplicate of this transmittal is enclosed for this purpose.

5. Foreign Search Reports

A copy of the PCT International Search Report from a counterpart application is enclosed. Legible copies of all items listed in Form PTO-1449 accompany this information statement. Cumulative patents or publications identified in the attached PCT Search Report are not enclosed.

The Applicant respectfully requests that:

- a. The Examiner consider the cited information in reaching a determination concerning the patentability of the pending claims; and
- b. The enclosed Form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

The person making this statement is the attorney who signs below on the basis of the

By:

information in the attorney's file.

2/1//

Byron V. Olsen, Reg. No. 42,960

Attorney for Applicant
GTC Biotherapeutics, Inc.
175 Crossing Blvd., Suite 410
Framingham, MA 01702

T.1. 4(500) (61.0150 B. 4(500)

Tel. #(508) 661-8150 Fax #(508) 370-3797

Approved for use through 10/31/2002 OMB 0651-0031

Attorney Docket Number | GTC-42 (10275-137001)

+ 420

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a OMB control number

/	Comp	lete if Known
Substitute for form 1449A/PTO	Application Number	09/398,610
INFORMATION DISCLOSURE	Filing Date	9/17/1999
STATEMENT BY APPLICANT	First Named Inventor	Michael Edge
(use as many sheets as necessary)	Art Unit	1632
(and an many sheets as necessary)	Examiner Name	Anne Marie Sabrina Wehbe
1 1 1		

2

of

Sheet


	-,		U.S. PA	TENT DOCUMENTS		
Examiner Initials	Cite No. ¹	Document Number Number - Kind Code ² (i	f known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-				
	ļ	US-				
·	ļ	US-				
		US-				
	<u>L</u>	US-				
		US-				
		US-				-CENTE
		US-			P	FOEIVE.
		US-				
		US-				MAY 2 3 2003
		US-				
		US-				H CENTER 1600
		US-			TEC	H CENIER 1001
		US-			1-L-V	
		US-				
		US-				
		US-				

			FO	REIG	PATENT DOCUM	IENTS		
Examiner Initials*	Cite No. ¹		eign Patent Docum Code ³ - Number ⁴ -Kir		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т°
		EP	0279582	A	08-24-1988	Rosen		
								-
	-							
	1							
								

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov. or MPEP 901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.



Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

				Comple	ete if Known
Substitute fo	substitute for form 1449A/PTO		Application Number	09398,610	
INFOR	MATION I	DISCI	LOSURE	Filing Date	9/17/1999
	MENT BY			First Named Inventor	Michael Edge
(use i	as many sheets as	nacassa	mı)	Group Art Unit	1632
		necessu		Examiner Name	Anne Marie Sabrina Wehbe
Sheet	2	of	2	Attorney Docket Number	GTC-42 (10275-137001)

	C	THER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No. ¹ 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		EBERT et al., "Induction of Human Tissue Plasminogen Activator in the Mammary Gland of Transgenic Goats", Bio/technology, Vol. 12, No. 7, pages 699-702 (1994)	
		NEWTON et al., "Angiogenin Single-Chain Immunofusions: Influence of Peptide Linkers and Spacers between Fusions Protein Domains", Biochemistry, American Chemical Society, Vol. 35, No. 3, pages 545-553 (1996)	
		NEWTON et al., "Cytotoxic Ribonuclease Chimeras Targeted Tumoricidal Activity In Vitro and In Vivo", The Journal of Biological Chemistry, Vol. 267, No. 27, pages 19572-19578 (1992)	
	-	11/	FD
		RECEIV	
		MAY 2.3	2003
		RECEIV MAY 2.3 TECH CENTER	1600 20
			_
Examiner	Τ	Date	
Signature		Considered	J



*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English translation is attached. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231